SEC Form 4
Repligen Corp (RGEN) insider trading
In the 12 months to Oct 23, 2026, 5 RGEN insiders reported open-market sales of $15.3M across 13 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $15.3M
- 13 filings · 5 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 10 of 13
- $11.8M of $15.3M sold (77%)
Who traded RGEN, and when
- Sale
- Sale, pre-arranged (10b5-1)
RGEN daily close from Oct 23, 2025 to Oct 23, 2026, between $102.87 and $194.57, last $178.21. 13 sale and 0 purchase filings by 5 insiders, marked at their filing dates. Olivier Loeillot, Chief Executive Officer: sold $7.7M across 7 filings, first filed Nov 26, 2025, last Oct 6, 2026. Anthony Hunt, Director: sold $7.0M across 2 filings, first filed Nov 13, 2025, last Nov 14, 2025. James Bylund, Chief Operating Officer: sold $331.3K across 1 filing, first filed Nov 19, 2025, last Nov 19, 2025. Jason K. Garland, CFO: sold $185.8K across 2 filings, first filed Jun 26, 2026, last Jul 17, 2026. Karen A. Dawes, Director: sold $44.3K across 1 filing, first filed Dec 18, 2025, last Dec 18, 2025.
Largest mark · tap a row for others
Anthony Hunt · Director
Filing 1 of 2 within a week · $7,014,218 total
Sale $3,921,940
25,000 shares at $156.88 avg
Filed Nov 13, 2025 · traded Nov 12
Pre-arranged (10b5-1) · close on filing date $150.56
Olivier Loeillot · Chief Executive Officer
Chief Executive Officer
$7.7M soldAnthony Hunt · Director
Director
$7.0M soldJames Bylund · Chief Operating Officer
Chief Operating Officer
$331.3K soldJason K. Garland · CFO
CFO
$185.8K soldKaren A. Dawes · Director
Director
$44.3K soldHas Repligen Corp's CEO sold stock?
Yes. Olivier Loeillot (CEO) sold 43,241 shares ($7.7M) between Nov 2025 and Oct 2026, all under a pre-arranged 10b5-1 plan.
Open-market trades
13 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Olivier Loeillot | Chief Executive Officer | $7.7M | — | 7 | 100% of sales | |
| Anthony Hunt | Director | $7.0M | — | 2 | 56% of sales | |
| James Bylund | Chief Operating Officer | $331.3K | — | 1 | — | |
| Jason K. Garland | CFO | $185.8K | — | 2 | 100% of sales | |
| Karen A. Dawes | Director | $44.3K | — | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Olivier Loeillot Chief Executive Officer | SalePre-arranged (10b5-1) | 5,535 | $187.29 | $1.0M | 45,788 | |
traded | Olivier Loeillot Chief Executive Officer | SalePre-arranged (10b5-1) | 12,946 | $190.00 | $2.5M | 48,369 | |
traded | Olivier Loeillot Chief Executive Officer | SalePre-arranged (10b5-1) | 5,426 | $180.00 | $976.7K | 48,369 | |
traded | Olivier Loeillot Chief Executive Officer | SalePre-arranged (10b5-1) | 3,035 | $165.90 | $503.5K | 48,369 | |
traded | Olivier Loeillot Chief Executive Officer | SalePre-arranged (10b5-1) | 5,426 | $180.00 | $976.7K | 54,246 | |
traded | Jason K. Garland CFO | SalePre-arranged (10b5-1) | 530 | $150.00 | $79.5K | 18,829 | |
traded | Jason K. Garland CFO | SalePre-arranged (10b5-1) | 733 | $145.00 | $106.3K | 19,359 | |
traded | Olivier Loeillot Chief Executive Officer | SalePre-arranged (10b5-1) | 3,832 | $140.00 | $536.5K | 54,246 | |
traded | Karen A. Dawes Director | Sale | 275 | $161.00 | $44.3K | 91,821 | |
traded | Olivier Loeillot Chief Executive Officer | SalePre-arranged (10b5-1) | 7,041 | $170.00 | $1.2M | 35,898 | |
traded | James Bylund Chief Operating Officer | Sale | 2,191 | $151.21 | $331.3K | 21,520 | |
traded | Anthony Hunt Director | Sale | 20,000 | $154.61 | $3.1M | 96,859 | |
traded | Anthony Hunt Director | SalePre-arranged (10b5-1) | 25,000 | $156.88 | $3.9M | 101,207 |
GET /stocks/filings/vX/form-4?tickers=RGEN&filing_date.gte=2025-10-23&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"RGEN"
],
"issuer_cik": "0000730272",
"owner_cik": "0001995525",
"accession_number": "0001628280-26-065238",
"form_type": "4",
"filing_date": "2026-10-06",
"period_of_report": "2026-10-05",
"issuer_name": "REPLIGEN CORP",
"issuer_trading_symbol": "RGEN",
"owner_name": "Loeillot Olivier",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Executive Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-05",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 4202,
"transaction_price_per_share": 190,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 45788,
"transaction_value": 798380,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025."
}
]
},
{
"tickers": [
"RGEN"
],
"issuer_cik": "0000730272",
"owner_cik": "0001995525",
"accession_number": "0001628280-26-065238",
"form_type": "4",
"filing_date": "2026-10-06",
"period_of_report": "2026-10-05",
"issuer_name": "REPLIGEN CORP",
"issuer_trading_symbol": "RGEN",
"owner_name": "Loeillot Olivier",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Executive Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-05",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 1333,
"transaction_price_per_share": 178.75,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 45788,
"transaction_value": 238273.75,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 44 records
- Option exercises9 records
- Tax withholding17 records
- Grants and awards17 records
- Other1 record
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
Build this yourself
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for RGEN every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.